Capstar Special Purpose Price, Forecast, Insider, Ratings, Fundamentals & Signals

Boston & austin, texas--(business wire)--gelesis, the maker of plenity®, an fda-cleared weight management approach, announced today the completion of its business combination with capstar special purpose acquisition corp. (nyse: cpsr) (“capstar”). the publicly traded company will be known as gelesis holdings, inc. (“gelesis” or “the company”) and will commence trading on the new york stock exchange under the ticker symbol “gls” on january 14, 2022. both gelesis inc. and capstar shareholders voted to approve the business combination. the transaction generated approximately $105 million in gross proceeds, which will be mainly used to support the broad launch of plenity. “we have developed the science and support to help make a difference in the lives of millions of americans who struggle with their weight, many of whom have never had a prescription option before,” said yishai zohar, founder and ceo of gelesis...

Boston--(business wire)--gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of plenity®, announced the appointment of senior financial executive ali bauerlein to its board of directors. ms. bauerlein brings extensive experience in sec reporting, sarbanes-oxley compliance, investor communications, strategic planning, business development, and corporate governance in high-growth direct-to-consumer, insurance rentals, and business-to-business revenue-generating companies. she co-founded inogen (nasdaq: ingn), a global medical technology company offering innovative respiratory products for use in the homecare setting, and led it from start-up through initial public offering and commercialization with $300m+ in annual revenue...

Boston--(business wire)--gelesis, the maker of plenity®, an fda-cleared weight management approach, has created an edible billboard in new york city’s astor place to challenge the idea that people can’t eat the foods they love while losing weight. the billboard features the message “who said you can’t eat what you love while losing weight?” and is made with thousands of seasonal holiday cakes. plenity will invite people to enjoy free dessert, reinforcing the notion that the holiday treats you love can fit into a balanced diet, no matter your health goals. like plenity’s core technology, the cakes are inspired by vegetables. they are made using natural ingredients like beetroot, carrot, and lemon...

Boston--(business wire)--gelesis, a consumer-focused biotherapeutics company, is proud to announce plenity®, an fda cleared weight management approach, is now broadly available across the united states to adults who meet the prescription criteria. the company is also pleased to announce the appointment of leading health and nutrition authority joy bauer, ms, rdn, cdn, as chief nutrition officer. in this new role, bauer will offer nutrition counseling and education for plenity members and engage with and educate healthcare professionals about the product. for adults who are looking to lose weight, there is often a lot standing in the way, like weight bias, fad diets, false promises, and the very real feeling of hunger...

Boston--(business wire)--gelesis announced today that leading u.s. direct-to-patient healthcare company ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, plenity®. plenity was initially made available through a beta launch in 2020, and demand quickly outpaced supply while gelesis worked to construct a larger manufacturing facility. gelesis’ first commercial-scale manufacturing line at the facility is now complete and validated. as gelesis’ exclusive telehealth partner in the u.s., ro provides patients with access to telehealth options for weight management including the ability to communicate with a healthcare provider and, if safe and appropriate, to receive a prescription for plenity through myplenity...

PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR).  The publicly-traded company will be Gelesis Holdings Inc and will begin trading on the New York Stock Exchange under the ticker symbol "GLS" from today.

A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.  The SPAC Deal: Gelesis announced a SPAC merger with Capstar Special Purpose Acquisition Corp (NYSE:CPSR).